Building a Diversified
Portfolio of Next-Generation Cancer Therapeutics

Our differentiated platform integrates bioinformatics, innate immunology, medicinal chemistry, and high-throughput biology to deliver first-in-class and best-in-class small molecules across foundational oncology modalities. 

Our assets target the fundamental biological mechanisms that enable cancers to evade the immune system and develop resistance to therapies.

Each asset is designed as a differentiated modality creating a portfolio with both mechanistic breadth and translational depth.

Drug Candidates

ENPP1 Inhibitor
(Best-in-Class)
Innate Immune Modulation
Solid tumors with STING suppression / cold tumors
See Mechanism
ADAR1 p150
(Zα-domain) Inhibitor
(First-in-Class)
Next-generation Targeted Therapies
Tumors resistant to checkpoint blockade / interferon-high phenotypes
See Mechanism
Tumor-targeted Radioligand Therapy
(First-in-Class)
Targeted Cell-Elimination Modality
Solid tumors expressing the proprietary target (e.g. - HCC, RCC)
See Mechanism

AVA-NP-695

Targets the earliest immune-sensing bottleneck in solid tumors and has strong rationale for combination with standard-of-care.

cGAS/STING pathway is a core innate anti-tumor immune pathway. In solid aggressive tumors, ENPP1 is overexpressed, shutting down STING signaling and preventing dendritic cell and T-cell activation.

AVA-NP-695 is designed to -
  • •
    Inhibit ENPP1 with high potency and selectivity
  • •
    Stabilize cGAMP to restore STING activation
  • •
    Drive type I IFN production & immune infiltration in tumors
  • •
    Reduce EMT-associated metastatic potential

AVA-ADR

Addresses a core tumor-intrinsic escape mechanism relevant across multiple solid tumor types.

ADAR1 p150 edits double-stranded RNA to suppress innate immune activation, enabling tumors to evade interferon signaling and resist immunotherapy.

AVA-ADR is designed to -
  • •
    Selectively target the Zα-domain of ADAR1 p150
  • •
    Upregulate interferon pathway 
  • •
    Demonstrate synthetic lethality in high-IFN tumors
  • •
    Reverse resistance to checkpoint inhibitors

AVA-ERL

Enables development of first-in-class radiopharmaceutical for precise delivery of radiation to cancer cells.

AVA-ERL is a first-in-class tumor-specific radioligand for precision medicine.

AVA-ERL is designed to -
  • •
    Selectively bind tumor cells with high target expression
  • •
    Deliver focused radiation
  • •
    Kill cancer cells in a targeted manner 
  • •
    Minimize exposure to surrounding healthy tissue

Why Our Pipeline is Positioned for Success

Discuss partnership opportunities
Mechanistic Breadth
Each asset targets a different axis of tumor immune biology, blocking pathways that allow cancers to persist.
Modality-Agnostic Discovery
Diverse therapeutics from an integrated discovery framework enabling rapid expansion.
Translational Rationale
Aligned with well-established biological drivers of therapeutic failure and disease persistence.
Early Partnership Potential
Exploring synergistic combinations with immunotherapies, targeted therapies and radiopharmaceuticals.

Reach out to us

→

USA

Avammune Therapeutics, Inc. Pennsylvania

India

Avammune Lifesciences Private Limited #545/6, 1st Floor, Devarachikkanahalli Main Road, Bommanahalli, Bangalore 560068
080-41268499
© 2026 Avammune Therapeutics